ANAHEIM, Ca. (May 20, 2007) -- Prostate cancer is the third-leading cause of cancer deaths among American men and is most treatable when caught in its earliest stages. Research presented today during the 102nd Annual Scientific Meeting of the American Urological Association in Anaheim, Ca. provided further evidence supporting regular prostate-cancer screening and offered new insights into disease progression and the hormonal treatment of recurrent disease. A special session for media highlighting this research was held on May 20 at 9:00 a.m. PDT and was moderated by AUA spokesman Christopher L. Amling, M.D.

A SINGLE PSA MEASUREMENT IN MIDDLE AGE PREDICTS DIAGNOSIS OF ADVANCED PROSTATE CANCER UP TO 25 YEARS LATER IN AN UNSCREENED POPULATION (Abstract 1876)

Almost all advanced cancers could be found early by intense screening of at-risk patients, according to researchers from New York and Malmo, Sweden who analyzed samples taken from a population-based cohort of 21,277 men in Malmo, Sweden between 1974 and 1986 to determine whether initial PSA plasma levels correlated with future diagnosis of advanced disease.

Of the 21,277 cases, 498 men actually developed prostate cancer, and 161 suffered from advanced disease (greater than T3 or metastasis). Association between PSA levels and eventual development advanced disease was determined using conditional logistical regression. In men with a total PSA of .5, .75, 1., 1.5 and 2 ng/ml, the probability of being diagnosed with advanced disease by age 75 was 2 percent, 3 percent, 4 percent, 7 percent and 12 percent, respectively. Risk was highly concentrated, with 89 percent of advanced cancers occuring in men with the top 10 percent of PSA levels.

This abstract will be presented during Moderated Poster Session 59 on Wednesday, May 23 starting at 1:00 p.m.

CLINICAL AND PATHOLOGICAL FEATURES OF SCREEN VS. NON-SCREEN DETECTED PROSTATE CANCERS: IS THERE A DIFFE
'"/>

Contact: Wendy Isett
wisett@auanet.org
410-689-3789
American Urological Association
20-May-2007